About Dr. Zhu Wei
Dr. Zhu Wei (朱玮) is a Chief Physician (主任医师) in the Department of Thyroid and Breast Surgery at Zhongshan Hospital, Fudan University — one of Shanghai's most prestigious academic medical centers. With deep expertise in thyroid cancer surgery and thyroid tumor management, Dr. Zhu practices within one of Shanghai's strongest thyroid and breast surgery departments, combining surgical precision with a comprehensive understanding of thyroid oncology.
Thyroid cancer is the most rapidly rising cancer globally, with incidence increasing across all age groups and regions. While the majority of thyroid cancers have an excellent prognosis with appropriate treatment, outcomes are highly dependent on the quality of the initial surgery — making the choice of surgeon one of the most consequential decisions a thyroid cancer patient will make. Dr. Zhu's experience at Zhongshan Hospital's high-volume thyroid surgery program ensures that patients receive technically precise surgery with optimal oncological outcomes.
Clinical Expertise
- Thyroid cancer surgery — total thyroidectomy and hemithyroidectomy for papillary, follicular, medullary, and anaplastic thyroid carcinoma, with appropriate central and lateral neck dissection
- Minimally invasive thyroid surgery — endoscopic and robotic-assisted thyroidectomy via remote access approaches (transoral, transaxillary, retroauricular) that leave no visible neck scar — a significant consideration for younger patients and those with cosmetic concerns
- Thyroid tumor surgery — surgical management of benign thyroid nodules, goiter, and Graves' disease requiring operative intervention
- Recurrent laryngeal nerve preservation — intraoperative nerve monitoring (IONM) to protect the recurrent laryngeal nerve and preserve voice function during thyroid surgery
- Parathyroid preservation — techniques to identify and preserve parathyroid glands during thyroidectomy, minimizing the risk of postoperative hypoparathyroidism and hypocalcemia
- Locally advanced thyroid cancer — surgical management of tumors with extrathyroidal extension, tracheal or esophageal involvement, or extensive lymph node metastases
- Multidisciplinary treatment coordination — integration of surgery with radioactive iodine (RAI) therapy, TSH suppression, targeted therapy (lenvatinib, sorafenib, selpercatinib), and external beam radiation for advanced disease
Why Dr. Zhu Wei?
The quality of the initial thyroid cancer surgery is the single most important determinant of long-term outcomes. An incomplete initial resection — leaving behind positive margins or unrecognized lymph node metastases — significantly increases the risk of recurrence and may necessitate more extensive reoperation, which carries higher complication rates. Dr. Zhu's experience at Zhongshan Hospital's high-volume thyroid surgery program ensures that patients receive a complete, oncologically sound operation from the outset.
For patients concerned about surgical scarring — particularly younger women, for whom a visible neck scar can have significant quality-of-life implications — Dr. Zhu's expertise in minimally invasive and remote-access thyroid surgery offers a meaningful alternative to conventional open thyroidectomy. Transoral and transaxillary approaches, when performed by experienced surgeons, achieve equivalent oncological outcomes with no visible neck incision.
Zhongshan Hospital's thyroid and breast surgery department is recognized as one of Shanghai's strongest in this specialty, with a high annual surgical volume that translates directly into surgical expertise and low complication rates.
Hospital: Zhongshan Hospital, Fudan University
Zhongshan Hospital is one of China's most prestigious academic medical centers, consistently ranked among the top hospitals in the country. Affiliated with Fudan University School of Medicine, it is internationally recognized across multiple specialties including hepatology, cardiology, and oncology. The Department of Thyroid and Breast Surgery combines high surgical volume with academic rigor, offering patients access to the latest surgical techniques, intraoperative monitoring technology, and a multidisciplinary tumor board for complex cases.
About Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy and the fastest-rising cancer globally, with incidence increasing by approximately 3% per year. Key facts for international patients:
- Papillary thyroid carcinoma (PTC): the most common subtype (85–90%); excellent prognosis with 10-year survival >95% for low-risk disease; surgery is the primary treatment
- Follicular thyroid carcinoma (FTC): second most common (5–10%); tends to spread hematogenously to lungs and bone; total thyroidectomy followed by RAI is standard
- Medullary thyroid carcinoma (MTC): arises from parafollicular C-cells; 25% are hereditary (RET mutation); calcitonin is the tumor marker; RET inhibitors (selpercatinib, pralsetinib) are approved for advanced disease
- Anaplastic thyroid carcinoma (ATC): rare but highly aggressive; BRAF V600E mutation present in ~45%; dabrafenib + trametinib combination is approved for BRAF-mutated ATC
- Minimally invasive surgery: transoral vestibular approach (TOETVA) and transaxillary robotic thyroidectomy are established techniques at high-volume centers; no visible scar
- Intraoperative nerve monitoring (IONM): continuous monitoring of recurrent laryngeal nerve function during surgery reduces the risk of permanent voice change
- Radioactive iodine (RAI): used post-surgery for remnant ablation and treatment of metastatic differentiated thyroid cancer; requires TSH stimulation (thyroid hormone withdrawal or recombinant TSH)
- Targeted therapy: lenvatinib and sorafenib for RAI-refractory differentiated thyroid cancer; selpercatinib and pralsetinib for RET-mutated MTC and PTC; dabrafenib + trametinib for BRAF V600E-mutated ATC
What to Prepare Before Your Consultation
To enable Dr. Zhu's team to conduct a thorough remote case review, international patients should prepare:
- Neck ultrasound report with measurements and characteristics of thyroid nodules and lymph nodes
- CT scan of the neck and chest with contrast (for locally advanced or metastatic disease)
- Fine needle aspiration (FNA) cytology or core biopsy pathology report
- Thyroid function tests: TSH, free T4, free T3
- Tumor markers: thyroglobulin (Tg) and anti-Tg antibodies (for differentiated thyroid cancer); calcitonin and CEA (for medullary thyroid cancer)
- Genetic testing results if available (RET, BRAF, RAS mutations)
- Prior treatment records if previously operated or treated with RAI or targeted therapy
- Vocal cord assessment (laryngoscopy report) if voice changes are present
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Dr. Zhu Wei and the Zhongshan Hospital thyroid surgery team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Dr. Zhu's team
- Full translation of ultrasound reports, pathology, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 Kommentare